Abstract
This study evaluates the outcome of myeloablative chemo-radiotherapy and autologous stem cell transplantation (ASCT) in children with Hodgkin's disease (HD). Twenty children aged 5 to 18 years (median 10.8 years) at diagnosis, with relapsed, refractory or very poor prognosis HD, underwent ASCT in eight hospitals of our country. Status at transplant was: second complete remission (CR2): n = 12; further cr (cr >2): n = 3, partial remission (PR): n = 2, relapse: n = 2 and first CR (CR1): n = 1. Eighteen patients received chemotherapy-based conditioning regimens: cyclophosphamide, carmustine and etoposide (CBV): 11 (55%), carmustine, etoposide, cytarabine and melphalan (BEAM): 5, other: 2; and two patients were conditioned with TBI/Cy. Peripheral blood (PB) was the source of progenitor cells in 12 patients, BM in seven, and BM plus PB, in one. All patients engrafted. One patient died of sepsis and multiorgan failure at day 28 after transplantation. All four patients with measurable disease (PR or relapse) at transplantation attained complete remission. Five patients relapsed 5–34 months after transplant (median: 11 months). Eighteen children remain alive with a median survival time of 40 months. The projected 5-year overall survival and event-free survival (EFS) rates were 0.95 and 0.62. High-dose therapy with stem cell rescue can lead to durable remissions in children with advanced HD. Bone Marrow Transplantation (2000) 25, 31–34.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 1994 83: 1193–1199
Nademanee A, O'Donnell MR, Synder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors Blood 1995 85: 1381–1390
Biermann PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy Ann Oncol 1996 7: 151–156
Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplant for recurrent or refractory Hodgkin's disease: analysis of Stanford University results and prognostic indices Blood 1997 89: 801–813
Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease Blood 1997 89: 814–822
Burns LJ, Daniels KA, McGlave PB . Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival Bone Marrow Transplant 1995 16: 13–18
Carella AM, Prencipe E, Pungolino E et al. Twelve years’ experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD protocol Leuk Lymphoma 1996 21: 63–70
Fleurys J, Legros M, Colombart P et al. High-dose therapy and autologous bone marrow transplantation in first complete remission or partial response for poor prognosis Hodgkin's disease Leuk Lymphoma 1996 20: 259–266
Bradley SJ, Pearce R, Taghipour G et al. First remission autologous bone marrow transplantation for Hodgkin's disease. Preliminary EBMT data Leuk Lymphoma 1996 15: (Suppl.1) 51–53
Sureda A, Mataix R, Hernández-Navarro F et al. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission. A retrospective study from the Spanish GEL-TAMO cooperative group Bone Marrow Transplant 1997 20: 283–288
Hutchinson RJ, Fryer CJH, Davis PCh . MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group phase III trial J Clin Oncol 1998 16: 897–906
Hunger SP, Link MP, Donaldson SS . ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience J Clin Oncol 1994 12: 2160–2166
Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD J Clin Oncol 1997 15: 528–534
Arranz R, Tomás JF, Gil-Fernández JJ et al. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant Bone Marrow Transplant 1998 21: 779–786
Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant J Clin Oncol 1993 11: 704–711
Baker KS, Gordon BG, Gross TG et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents J Clin Oncol 1999 17: 825–831
Moreau P, Fleury J, Brice P et al. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry Bone Marrow Transplant 1998 21: 787–793
Sankila R, Garvicz S, Olsen JH et al. Risk of subsequent malignant neoplasms among 1641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries J Clin Oncol 1896 14: 1442–1446
Wolden SL, Lamborn KR, Cleary SF . Second cancers following pediatric Hodgkin's disease J Clin Oncol 1998 16: 536–544
Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy Blood 1994 83: 3780–3786
Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single center eight-year study of 155 patients Blood 1993 81: 1137–1145
Acknowledgements
We thank Miss Thelma Alvis for her help with this manuscript.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Verdeguer, A., Pardo, N., Madero, L. et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Bone Marrow Transplant 25, 31–34 (2000). https://doi.org/10.1038/sj.bmt.1702094
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702094
Keywords
This article is cited by
-
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma
Bone Marrow Transplantation (2022)
-
Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience
Bone Marrow Transplantation (2020)
-
Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma
Annals of Hematology (2016)
-
Single-agent high-dose melphalan followed by auto-SCT for relapsed and refractory Hodgkin lymphoma in children and adolescents
Bone Marrow Transplantation (2012)
-
High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma
Bone Marrow Transplantation (2010)